2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary - Heidenreich, Paul A.; Bozkurt, Biykem; Aguilar, David; Allen, Larry A.; Byun, Joni J.; Colvin, Monica M.; Deswal, Anita; Drazner, Mark H.; Dunlay, Shannon M.; Evers, Linda R.; Fang, James C.; Fedson, Savitri E.; et al. (Journal of the American College of Cardiology, 2022)
Keywords: ACC/AHA Clinical Practice Guidelines; ACE inhibitors; acute decompensated heart failure; angiotensin and neprilysin receptor antagonist; angiotensin receptor antagonist; atrial fibrillation; beta blockers; cardiac amyloidosis; cardiac failure; cardio-oncology; cardiogenic shock; cardiomyopathy; cardiomyopathy in pregnancy; Cardiovascular; chronic heart failure; congestive heart failure; diabetes; guideline-directed medical therapy; heart failure; heart failure rehabilitation; heart failure with mildly reduced ejection fraction; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; Internal Medicine; mineralocorticoid receptor antagonists; mitral regurgitation; palliative care; reduced ejection fraction; right heart pressure; sacubitrilvalsartan; SGLT2 inhibitors; social determinants of health; sodium glucose co-transporter 2; systolic heart failure; valvular heart disease; ACC/AHA Clinical Practice Guidelines; right heart pressure; angiotensin receptor antagonist; chronic heart failure; cardiogenic shock; beta blockers; palliative care; reduced ejection fraction; atrial fibrillation; heart failure with preserved ejection fraction; heart failure with mildly reduced ejection fraction; congestive heart failure; valvular heart disease; mineralocorticoid receptor antagonists; sacubitrilvalsartan; cardiomyopathy; heart failure with reduced ejection fraction; SGLT2 inhibitors; heart failure; social determinants of health; mitral regurgitation; systolic heart failure; acute decompensated heart failure; cardio-oncology; guideline-directed medical therapy; angiotensin and neprilysin receptor antagonist; cardiomyopathy in pregnancy; heart failure rehabilitation; cardiac amyloidosis; sodium glucose co-transporter 2; ACE inhibitors; diabetes; cardiac failure